sprite-preloader
Montag, 26.09.2016 Börsentäglich über 12.000 News von 546 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A11QW5 ISIN: DE000A11QW50 Ticker-Symbol: ECX 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Prime Standard
DAX International Mid 100
1-Jahres-Chart
EPIGENOMICS AG Chart 1 Jahr
1-Woche-Intraday-Chart
EPIGENOMICS AG 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
5,041
5,078
12:27
5,034
5,069
12:27
23.09.2016 | 18:12
(103 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

DUBLIN, September 23, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Fecal Occult Testing market 2016-2020" report to their offering.

The global fecal occult testing market to grow at a CAGR of 4.82% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global fecal occult testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fecal occult testing products used to perform colorectal cancer screening.

Fecal occult testing is simple and non-invasive in nature, thereby increasing its preference among many physicians. The results of few of the fecal occult tests can be obtained rapidly through point-of-care (POC) test kits such as Alere's Clearview iFOB, and Beckman Coulter's Hemoccult II SENSA. For instance, the Clearview iFOB test is based on human hemoglobin and gastrointestinal bleeding, and can provide results in five minutes. Beckman Coulter's Hemoccult II SENSA slides allow people to collect fecal samples at home settings and send them to hospitals, laboratories, and diagnostic centers.

Direct-to-consumer laboratory testing is an important trend spurring this market's growth prospects. Direct-to-consumer laboratory testing allows people to receive test kits and send samples to laboratories. Many people in the age group 60 years and above in developed countries such as Australia, the US, the UK, and Germany opt for direct-to-consumer genetic testing. These products can be selected online services and can be accessed from any geographical location. The cost of these products is less compared with traditional genetic testing kits. Direct-to-consumer genetic testing kits cost $100-$1,200. Companies or laboratories such as Color Genomics in the US and Mapmygenome in India offer direct-to-consumer genetic testing services that help identify or screen for colorectal cancer.

According to the report, shift toward patient-centered model (POC FITs) for home use is one of the ley drivers contributing to the growth of this market. Various government and non-government initiatives have helped increase awareness and research data about colorectal cancer. This presents significant opportunities for improving cancer management. Devices used for testing at or near the site of the patient are known as POC devices. These devices can be used at home settings; however, people need to consult their physicians for further disease diagnosis and treatment. These devices can also be used outside a laboratory and in hospitals and clinics.

Key vendors

  • Beckman Coulter
  • Eiken Chemical
  • Epigenomics
  • Quidel

Other prominent vendors

  • Abbott Laboratories
  • AccuBioTech
  • Applied Proteomics
  • ASAN PHARM.
  • Assure Tech.
  • BIOHIT Healthcare
  • EDP Biotech
  • FUJIREBIO
  • GeneNews
  • NanoRepro
  • Nantong Egens Biotechnology
  • Orion Diagnostica
  • Polymedco
  • Quest Diagnostics
  • Randox
  • VolitionRx

For more information about this report visit http://www.researchandmarkets.com/research/zzpwr8/global_fecal

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


© 2016 PR Newswire